Tracing the Treatment Journey Using Real-World Data
Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous... In DRG Blog/ September, 2019 Breast Cancer Drugs Serve a New Master: The Clinical Pathway
Any company marketing a drug in the United States knows the drill: good access depends on preferred formulary placement and avoiding onerous prior... In DRG Blog/ June, 2019 Checkpoint Inhibitors: 9 Key Takeaways for Biopharma Strategists
The following is an excerpt from the eBook Checkpoint Inhibitors: Takeaways and Best Practices for Strategic Planning It’s very clear that the race... In DRG Blog, Drug Watch/ January, 2019 PARP Inhibitors Updates from ESMO 2018
PARP inhibitors have generated huge excitement with their recent approvals in ovarian and breast cancer, these agents are making a meaningful impact... In DRG Blog, Drug Watch/ October, 2018 ESMO 2018: Expanding Horizons in Advanced Breast Cancer
About 28,000 attendees from over 130 countries gathered last week at the ESMO 2018 Congress held in Munich, Germany, to hear the latest and greatest... In DRG Blog, Drug Watch/ October, 2018 Drug Manufacturers, PBMs, and Insurers Beware
California Lawmakers Are Fixed on You Amid the rush of states clamping down on pharmaceutical companies, California has set the pace for a showdown... In DRG Blog, Drug Watch, Market Access/ October, 2018 Treatment Sequencing: Navigating the Complex System of Pathways in the Oncology Ecosystem
Presenter: Rachel Webster, Principal Director, DRG Oncology Webinar Length: 9 minutes In today’s landscape, it’s challenging to get an... In downloads/ July, 2018 Real-World Evidence Reveals Low Dosing Compliance in Multiple Myeloma
An Examination of Patient Data in Japan The transformation of treatment paradigms in oncology continues unabated as the last two decades saw an... In DRG Blog, Drug Watch, Market Access/ June, 2018 Under ISP, How Will your Plan Assess an Oncology Drug’s Value for an Indication?
Key finding: For their indication-specific pricing (ISP) programs, 52% of surveyed MCOs identified phase II/III trial data and... In DRG Blog, Drug Watch, Market Access/ June, 2018 EHA 2018: Shifting Paradigms in NHL
Stockholm was awash with some of the biggest names in hematology one June weekend as the city played host to the annual meeting of the European... In DRG Blog, Drug Watch, Market Access/ June, 2018 ASCO 2018: Innovative Therapies for Bladder Cancer Outside of the Immune Space
The unprecedented and rapid market entry of five immune checkpoint inhibitors—Tecentriq, Opdivo, Keytruda, Imfinzi, and Bavencio— has... In DRG Blog, Drug Watch, Market Access/ June, 2018 ASCO 2018: Merck Set to Consolidate its Dominant Position in First-line Metastatic NSCLC
The landscape for first-line metastatic NSCLC without driver mutations has been shifting constantly over the last few months, with a truly dizzying... In DRG Blog, Drug Watch, Market Access/ June, 2018 ASCO 2018 Highlights Difficulties Developing Combinations with Immune Checkpoint Inhibitors
If oncology drug development is considered race to the market, the fever around combinations with immune checkpoint inhibitors is turning it into a... In DRG Blog, Drug Watch, Market Access/ June, 2018 PPMA Congress 2018: Innovative Contracting, RWD and More
In today’s global market access environment, pharmaceutical companies must consider the various headwinds and trends that will shape their future... In DRG Blog, Drug Watch, Market Access/ April, 2018 Phase III Epacadostat + Keytruda Trial Failure: How Will it Impact the Oncology Landscape?
Forecasting the likelihood of success of late-phase clinical trials in oncology is complex. Positive efficacy signals observed in early-phase trials... In downloads/ April, 2018 What Can We Learn About Treatment Sequencing In Oncology Using RWD?
Over the last two decades, the treatment paradigm for many cancer indications has been transformed beyond recognition. To fully appreciate the... In DRG Blog, Drug Watch, Market Access/ April, 2018 The Art of the Oncology Deal
The number of deals in the pharmaceutical space has the tendency to fluctuate, but in recent years there has been a proportional increase in the... In downloads/ March, 2018 Are Moderna’s Bets Worth $7.5 Billion?
Moderna Therapeutics has just completed a new $500 million round of funding, raising its market valuation to a staggering $7.5 billion. Even more jaw-... In DRG Blog, Drug Watch, Market Access/ February, 2018 Navigating The Road To Reimbursement And Optimizing Uptake For Oncology Agents In The EU5: Payer And Prescriber Perspectives On The Power Of Pivotal Trial Design
• The health technology assessment (HTA) bar is rising across the EU5 (France, Germany, Italy, Spain, UK) as payers come under increasing... In downloads/ January, 2018 DRG Epidemiology’s Global Lung Cancer Forecast, 2017-2027
This live session took place on Wednesday, December 6th, 2017. Wei Wei Zhang presented DRG’s epidemiological forecast of all those living with lung... In downloads/ December, 2017